Semaglutide and Aging: What the Study Shows

In 2026, a UC San Diego team reported that semaglutide changed several epigenetic aging-clock measurements in a randomized, placebo-controlled trial. The headline number is about 9% slower on the DunedinPACE clock, a blood test that estimates how fast a person is aging biologically. The details matter: 84 people, all with HIV-associated lipohypertrophy (excess fat build-up, mainly around the abdomen), followed for 32 weeks, in an analysis run after the trial had finished ("post hoc").

The second study people cite is tirzepatide's SURMOUNT-MMO, a large trial of hard health outcomes. Its design addresses clinical outcomes rather than an aging-clock measurement.

Primary source: the peer-reviewed epigenetic-clock analysis in Nature Communications.

The study in short

Where: Nature Communications, 2026. Lead author Michael Corley, UC San Diego
Design: a post hoc epigenetic analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial of semaglutide
People: 108 adults with HIV-associated lipohypertrophy were randomized; 84 had paired blood samples at baseline and week 32
Result: about 9% lower DunedinPACE. Signals also appeared on PCGrimAge (a clock trained to reflect mortality risk) and on organ-system clocks linked to inflammation, heart, brain, liver, kidney, blood and metabolic health
The authors' caution: larger trials are needed to confirm the findings, see how long the effect lasts, and cover a broader population

What "9% slower" means

DunedinPACE estimates a rate. A value of 1.0 means one year of biological aging per calendar year. A 9% lower value means the measured pace over the study period was slower. It does not mean participants became 9% younger, and it is not a lifespan figure.

What is an epigenetic clock, and does it predict lifespan?

Epigenetic clocks read DNA methylation patterns (chemical tags on DNA) in blood to estimate age or pace of aging. Faster clocks associate with higher disease and death risk across groups in large studies. It hasn't been shown that shifting a clock with a drug changes how long an individual lives, and none of these clocks is an accepted regulatory surrogate for lifespan.

Does this apply to people without HIV?

Unknown. HIV-associated lipohypertrophy involves visceral fat and chronic inflammation, and semaglutide reduces both; the authors propose those reductions as the likely drivers. The analysis was also post hoc: aging clocks weren't the question the trial was designed to answer.

What will SURMOUNT-MMO answer?

SURMOUNT-MMO is a randomized, event-driven trial of tirzepatide versus placebo in about 15,000 adults with obesity and cardiovascular risk. The primary endpoint is time to first nonfatal heart attack, nonfatal stroke, coronary revascularization (a procedure to reopen blocked heart arteries), heart failure event or death. It is a hard-outcomes trial, not an aging trial.

Research use only. Not for human or veterinary use. Not approved by the Thai FDA. Educational content, not medical advice or a recommendation to use any compound.

Shop Semaglutide → Shop Tirzepatide →